Drug Profile
Research programme: kinase inhibitors - Aclaris Therapeutics
Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Confluence Life Sciences
- Developer Aclaris Therapeutics
- Class
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for research development in Cancer in USA
- 08 Aug 2017 Confluence Life Sciences has been acquired by Aclaris Therapeutics
- 07 Jan 2015 Research programme: kinase inhibitors - Confluence Life Sciences is available for licensing as of 07 Jan 2015. http://www.confluencelifesciences.com